LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2024 financial and operational ...

Virginia Cancer Specialists, a respected leader in providing community-based cancer care in Northern VA for more than ...

Robust financial performance driven by full year 2024 royalty revenue growth of 28%Reiterating 2025 financial guidance of $180-$200 million in ...

Q4 2024 Earnings Call Transcript February 27, 2025 Ligand Pharmaceuticals Incorporated misses on earnings expectations.

Kangpu Biopharmaceuticals, Ltd. ("Kangpu") today announced that the Company has received IND approval from the CDE (Center for Drug Evaluation) of China National Medical Products Administration (NMPA) ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...

Jon Huertas (This Is Us) and Brooklynn Prince (The Florida Project) are set to headline the indie feature California Scenario ...

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

Katharine is Eurogamer's Managing Editor and primary spreadsheet keeper. She heads up Eurogamer's reviews and feature sections, but can occasionally be found writing guides and the odd news story ...

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...